<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Amgen Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/amgen-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MITI) Micromet Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/12/09/miti-micromet-analyst-maintains-neutral-on-shares-2/88278</link>
		<comments>http://www.stockbloghub.com/2011/12/09/miti-micromet-analyst-maintains-neutral-on-shares-2/88278#comments</comments>
		<pubDate>Fri, 09 Dec 2011 17:40:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88278</guid>
		<description><![CDATA[We have maintained a Neutral rating on Micromet, Inc. (MITI) with a target price of $7.00 per share following appraisal of third quarter 2011 results. Micromet’s third quarter 2011 loss per share came in at 21 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 13 cents per share (also adjusting for the change in fair value of warrants). Lower-than-expected revenues led to the wider loss in the quarter. Revenues at Micromet were down almost 33% from the prior-year period to $4.5 million in the third quarter of 2011 due to lower collaboration revenue. Moreover, revenues in the year-ago quarter were boosted by the presence of a milestone payment from AstraZeneca (AZN). Revenues were also much below the Zacks Consensus Estimate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/09/miti-micromet-analyst-maintains-neutral-on-shares-2/88278/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Begins New Trial</title>
		<link>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072</link>
		<comments>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072#comments</comments>
		<pubDate>Tue, 06 Dec 2011 19:36:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88072</guid>
		<description><![CDATA[Micromet Inc. (MITI) recently announced that it has begun a mid-stage registrational trial of its lead pipeline candidate, blinatumomab, in adult patients with B-precursor relapsed refractory acute lymphoblastic leukemia (ALL). The trial was advised to be conducted by the US Food &#38; Drug Administration (FDA) to support accelerated approval of blinatumomab. The trial is a single-arm study which will evaluate 65 patients with the primary endpoint of complete remission (CR) or CR with partial recovery of blood counts (CRh). Micromet expects to complete enrollment for the trial by year-end 2012. The mid-stage study will be followed by a late-stage trial (with a time dependent endpoint) to evaluate the safety and efficacy of blinatumomab versus chemotherapy in adult patients with relapsed refractory B precursor ALL. Design details of the late-stage trial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck Drug Candidate Presents New Data</title>
		<link>http://www.stockbloghub.com/2011/09/21/mrk-merck-drug-candidate-presents-new-data/83706</link>
		<comments>http://www.stockbloghub.com/2011/09/21/mrk-merck-drug-candidate-presents-new-data/83706#comments</comments>
		<pubDate>Wed, 21 Sep 2011 18:08:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83706</guid>
		<description><![CDATA[Merck (MRK) recently presented new clinical and pre-clinical data on its phase III pipeline candidate, odanacatib. Odanacatib is an investigational cathepsin K (cat-K) inhibitor which is being developed for the treatment of osteoporosis in post-menopausal women. Results were presented from a phase IIb clinical study extending to five years. Merck said that postmenopausal women being treated with odanacatib 50 mg weekly continuously for five years experienced an increase in bone mass density (BMD) at the lumbar spine (11.9% increase from baseline), femoral neck (9.8% increase from baseline), hip trochanter (10.9% increase from baseline), and total hip (8.5% increase from baseline). However, adverse and serious adverse experiences were higher in the odanacatib treatment group. Adverse experiences and serious adverse experiences were 89% and 22%, respectively in the odanacatib arm, compared to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/21/mrk-merck-drug-candidate-presents-new-data/83706/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Loss Less Than Analyst Estimates &#8211; Revenues Rise</title>
		<link>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906</link>
		<comments>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:31:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80906</guid>
		<description><![CDATA[Micromet Inc.’s (MITI) second quarter 2011 loss per share came in at 19 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 15 cents per share (also adjusting for the change in fair value of warrants). The loss was, however, narrower than the Zacks Consensus Estimate of a loss of 21 cents due to higher-than-expected revenues. Loss widened from the prior year due to higher operating expenses which more than offset the rise in revenues. Quarterly Details Revenues at Micromet were up 7.8% to $7.1 million in the second quarter of 2011 on the back of higher collaboration revenue. Revenues were also above the Zacks Consensus Estimate of $6 million. Operating expenses during the reported quarter climbed approximately 56% over the prior-year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Company News for August 1, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/08/01/amgn-company-news-for-august-1-2011-corporate-summary/80308</link>
		<comments>http://www.stockbloghub.com/2011/08/01/amgn-company-news-for-august-1-2011-corporate-summary/80308#comments</comments>
		<pubDate>Mon, 01 Aug 2011 16:40:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AmeriGas Partners LP]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[APU]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[Eagle Bulk Shipping Inc]]></category>
		<category><![CDATA[EGLE]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Newell Rubbermaid Inc.]]></category>
		<category><![CDATA[NWL]]></category>
		<category><![CDATA[Southwest Gas Corporation]]></category>
		<category><![CDATA[STEC]]></category>
		<category><![CDATA[STEC Inc.]]></category>
		<category><![CDATA[SWX]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80308</guid>
		<description><![CDATA[•    Chevron Corp. (NYSE:CVX) reported a jump in its second-quarter 2011 profits, benefiting from higher oil prices and stronger refining margins. Earnings per share (excluding adjustments for foreign-currency effects) came in at $3.89, beating the Zacks Consensus Estimate of $3.55 and the year-ago adjusted profit of $2.58 •    Amgen Inc. (NASDAQ:AMGN) reported second quarter earnings per share of $1.35, above the Zacks Consensus Estimate of $1.30, and 0.7% higher than year-ago earnings •    Merck &#38; Co. Inc.’s (NYSE:MRK)  earnings per share (excluding special items) for the second quarter of 2011 came in at 95 cents, in line with the Zacks Consensus Estimate, but 10.5% above year-ago earnings. •    Newell Rubbermaid Inc. (NYSE:NWL) reported second quarter of 2011 earnings of $0.46 per share, down from $0.51 a share in the year-ago ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/01/amgn-company-news-for-august-1-2011-corporate-summary/80308/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Debt Ceiling Debate and Dismal GDP Add To Market Stress</title>
		<link>http://www.stockbloghub.com/2011/07/31/amgn-debt-ceiling-debate-and-dismal-gdp-add-to-market-stress/80203</link>
		<comments>http://www.stockbloghub.com/2011/07/31/amgn-debt-ceiling-debate-and-dismal-gdp-add-to-market-stress/80203#comments</comments>
		<pubDate>Sun, 31 Jul 2011 19:36:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACI]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Arch Coal Inc]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[NEM]]></category>
		<category><![CDATA[Newmont Mining Corporation]]></category>
		<category><![CDATA[SBUX]]></category>
		<category><![CDATA[Starbucks Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80203</guid>
		<description><![CDATA[The debt debate continues to steal the spotlight from earnings and economic reports. The stock market has lost ground in recent days due to this uncertain environment even as corporate earnings reports have broadly come ahead of expectations. With both sides in the debt debate sticking to their positions ahead of the Tuesday deadline, stocks will likely remain on edge today as well. The dismal GDP adds to the market&#8217;s woes. While the GDP report was expected to be on the soft side, the extent of the weakness and the negative revisions to the prior quarter&#8217;s numbers were very disappointing. The U.S. economy expanded at a lower-than-expected 1.3% rate in the second quarter, while the first quarter&#8217;s growth rate was sharply revised down to 0.4% from 1.9%. The softness is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/31/amgn-debt-ceiling-debate-and-dismal-gdp-add-to-market-stress/80203/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Beats Earnings Expectations &#8211; Updates Outlook</title>
		<link>http://www.stockbloghub.com/2011/07/30/amgn-amgen-beats-earnings-expectations-updates-outlook/80227</link>
		<comments>http://www.stockbloghub.com/2011/07/30/amgn-amgen-beats-earnings-expectations-updates-outlook/80227#comments</comments>
		<pubDate>Sat, 30 Jul 2011 19:54:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Energy Services of America Corporation]]></category>
		<category><![CDATA[ESA]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80227</guid>
		<description><![CDATA[Amgen (AMGN) reported second quarter earnings per share of $1.35, 5 cents above the Zacks Consensus Estimate and 0.7% above the year-ago earnings. Total revenues increased 4% to $3,959 million in the second quarter of 2011. Revenues topped the Zacks Consensus Estimate of $3,778 million. US revenues increased 7% during the quarter to $2,975 million. Meanwhile, international revenues increased 11% to $918 million. Foreign exchange (Fx) fluctuation boosted revenues by $34 million during the second quarter. The Quarter in Detail Second quarter total product sales increased 8% to $3,893 million. Revenues of Amgen’s erythropoiesis-stimulating agent (ESA) Aranesp fell 3% to $585 million (US: $241 million, down 10%; ex-US: $344 million, up 2%). US sales were down mainly due to a decline in demand that was partially offset by a price ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/30/amgn-amgen-beats-earnings-expectations-updates-outlook/80227/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Drug Earns Positive Committee for Medicinal Products for Human Use Opinion</title>
		<link>http://www.stockbloghub.com/2011/06/29/amgn-amgen-drug-earns-positive-committee-for-medicinal-products-for-human-use-opinion/77581</link>
		<comments>http://www.stockbloghub.com/2011/06/29/amgn-amgen-drug-earns-positive-committee-for-medicinal-products-for-human-use-opinion/77581#comments</comments>
		<pubDate>Wed, 29 Jun 2011 17:07:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77581</guid>
		<description><![CDATA[Amgen (AMGN) recently announced that it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for a label expansion for its oncology product, Vectibix. Amgen is looking to gain EU approval for the use of Vectibix in patients with wild-type KRAS metastatic colorectal cancer (mCRC) as a first-line treatment in combination with FOLFOX and second-line treatment in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). The CHMP had previously adopted a negative opinion regarding Amgen’s marketing authorization application for Vectibix’ label expansion. Amgen filed an appeal against the decision in March 2011 requesting the EMA to re-examine the CHMP’s opinion. With the CHMP now changing its view, a final decision from the European regulatory ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/amgn-amgen-drug-earns-positive-committee-for-medicinal-products-for-human-use-opinion/77581/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Seeks Label Expansion</title>
		<link>http://www.stockbloghub.com/2011/06/29/amgn-amgen-seeks-label-expansion/77769</link>
		<comments>http://www.stockbloghub.com/2011/06/29/amgn-amgen-seeks-label-expansion/77769#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:44:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77769</guid>
		<description><![CDATA[Amgen (AMGN) is looking to gain approval for additional indications of Xgeva. The company recently submitted a supplemental Biologics License Application (sBLA) seeking US Food and Drug Administration (FDA) approval for Xgeva (denosumab) for the reduction of the risk of developing bone metastases in men with castrate-resistant prostate cancer. Approval would make Xgeva the first therapy for the prevention or delay of the spread of cancer to the bone. Amgen’s application is based on data from a pivotal phase III study (&#8217;147) that was conducted in 1,432 men with castrate-resistant prostate cancer. Results from the ‘147 study showed that Xgeva improved median bone metastasis-free survival by 4.3 months compared to placebo. Xgeva sales should receive a major boost if Amgen succeeds in gaining approval for the prevention of bone metastases ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/amgn-amgen-seeks-label-expansion/77769/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs Boosts Immunology Pipeline</title>
		<link>http://www.stockbloghub.com/2011/06/24/abt-abbott-labs-boosts-immunology-pipeline/77422</link>
		<comments>http://www.stockbloghub.com/2011/06/24/abt-abbott-labs-boosts-immunology-pipeline/77422#comments</comments>
		<pubDate>Fri, 24 Jun 2011 22:04:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77422</guid>
		<description><![CDATA[Abbott Labs (ABT) recently entered into a global agreement with Biotest AG for the development and commercialization of a novel anti-CD4 antibody, BT-061. The Candidate: BT-061 The deal is focused on the development and commercialization of BT-061 for the treatment of rheumatoid arthritis (RA) and psoriasis. BT-061 is currently being evaluated in phase II studies for RA and psoriasis. Moreover, the candidate’s potential to be used for other immune-related diseases is being evaluated in preclinical studies. BT-061 could be differentiated from other anti-CD4 antibodies as it does not cause depletion of CD4 positive T-cells which would lead to weakened immune responses. Terms of the Deal Per the terms of the agreement, BT-061 will be co-promoted by Abbott Labs and Biotest in the five major European markets: Germany, France, United Kingdom, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/abt-abbott-labs-boosts-immunology-pipeline/77422/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Beats First Quarter Estimates &#8211; Maintains Outlook</title>
		<link>http://www.stockbloghub.com/2011/04/27/amgn-amgen-beats-first-quarter-estimates-maintains-outlook/72064</link>
		<comments>http://www.stockbloghub.com/2011/04/27/amgn-amgen-beats-first-quarter-estimates-maintains-outlook/72064#comments</comments>
		<pubDate>Wed, 27 Apr 2011 17:52:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72064</guid>
		<description><![CDATA[Amgen (AMGN) reported first quarter earnings per share of $1.32, 3 cents above the Zacks Consensus Estimate of $1.29 and 3.1% above year-ago earnings. Higher revenues, a lower tax rate and lower share count helped drive first quarter results. Including one-time items, earnings increased 2% to $1.20 in the first quarter of 2011. Total revenues increased 3.2% to $3,706 million in the first quarter of 2011. Revenues topped the Zacks Consensus Estimate of $3,662 million. US revenues increased 4% during the quarter to $2,778 million. Meanwhile, international revenues dropped 1% to $840 million. Foreign exchange (Fx) fluctuation negatively impacted revenues during the first quarter. While Xgeva was off to a strong start, Epogen performance disappointed. The Quarter in Detail First quarter total product sales increased 2.6% to $3,618 million. Revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/amgn-amgen-beats-first-quarter-estimates-maintains-outlook/72064/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Appeals EU Drug Opinion</title>
		<link>http://www.stockbloghub.com/2011/04/04/amgn-amgen-appeals-eu-drug-opinion/70440</link>
		<comments>http://www.stockbloghub.com/2011/04/04/amgn-amgen-appeals-eu-drug-opinion/70440#comments</comments>
		<pubDate>Mon, 04 Apr 2011 13:47:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70440</guid>
		<description><![CDATA[Amgen (AMGN) is appealing the negative recommendation issued by the Committee for Medicinal Products for Human Use (CHMP) for the use of Vectibix plus chemotherapy in patients with wild-type KRAS metastatic colorectal cancer (mCRC). The company has requested the European Medicines Agency (EMA) to re-examine CHMP’s opinion. Negative Opinion Issued in March 2011 The CHMP had adopted a negative opinion regarding Amgen’s marketing authorization application for Vectibix’s label expansion in March 2011. At that time, Amgen had said that it would appeal the opinion. Results from two studies (PRIME and ‘181) showed that Vectibix plus chemotherapy improved progression-free survival in patients with wild-type KRAS mCRC compared to only chemotherapy. Moreover, Amgen reported a higher response rate in the Vectibix arm compared to chemotherapy alone. Amgen is looking to drive Vectibix sales ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/04/amgn-amgen-appeals-eu-drug-opinion/70440/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AA) Stock Market News for January 25, 2011  &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/01/27/aa-stock-market-news-for-january-25-2011-market-news/65701</link>
		<comments>http://www.stockbloghub.com/2011/01/27/aa-stock-market-news-for-january-25-2011-market-news/65701#comments</comments>
		<pubDate>Thu, 27 Jan 2011 13:34:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Aluminum]]></category>
		<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[AA]]></category>
		<category><![CDATA[Alcoa Inc.]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[NVDA]]></category>
		<category><![CDATA[NVIDIA Corporation]]></category>
		<category><![CDATA[Sealed Air Corporation]]></category>
		<category><![CDATA[SEE]]></category>
		<category><![CDATA[Texas Instruments Inc.]]></category>
		<category><![CDATA[TXN]]></category>
		<category><![CDATA[VMC]]></category>
		<category><![CDATA[Vulcan Materials Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=65701</guid>
		<description><![CDATA[A strong rally led by natural resources and tech shares helped markets to close in the green with the Dow nearing its psychological 12000 mark for the first time since June 2008. Tech stocks zoomed after chip maker Intel announced increased dividends and possible buy back of shares. The Dow Jones Industrial Average gained 0.92% to end at 11,980.52. The S&#38;P 500 was up 0.58%, or 7.49 points, to close at 1,290.84 and, the tech-laden Nasdaq Composite Index rose 1.04% to 2,717.55. On the New York Stock Exchange, breadth of the market was on the positive side as for every 2,114 stocks that rose, 882 stocks ended in the red. Volumes were on the lighter side with only 7.02 billion shares traded, the lowest level recorded this year. Coming to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/01/27/aa-stock-market-news-for-january-25-2011-market-news/65701/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Stock Market News for Dec 15, 2010 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2010/12/15/amgn-stock-market-news-for-dec-15-2010-market-news/62397</link>
		<comments>http://www.stockbloghub.com/2010/12/15/amgn-stock-market-news-for-dec-15-2010-market-news/62397#comments</comments>
		<pubDate>Wed, 15 Dec 2010 21:04:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abercrombie & Fitch Company]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ANF]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[BBY]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Best Buy Company Inc]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[M]]></category>
		<category><![CDATA[Macy's]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Target Corporation]]></category>
		<category><![CDATA[TGT]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62397</guid>
		<description><![CDATA[On Tuesday, the markets closed almost flat after a muted view from the Federal Reserve about the economic recovery. However, stocks were helped marginally by the positive report on retail spending. The Dow Jones Industrial Average rose 0.4% to 11,476.54.The Standard &#38; Poor&#8217;s 500 was up 0.1% to 1,241.59.The Nasdaq Composite gained 0.1% to 2,627.72. On the New York Stock Exchange, breadth of the market was negatively biased as for every 17 stocks that fell, 13 stocks ended in the green with a consolidated volume of 957 million shares. The Federal Reserve sketched out a cautious outlook of the economy in its last scheduled meeting of the year. The Fed stated that the economic recovery has not been strong enough to reduce the unemployment rate. The Federal Reserve also said ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/15/amgn-stock-market-news-for-dec-15-2010-market-news/62397/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) Company News For December 14, 2010 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2010/12/14/aapl-company-news-for-december-14-2010-corporate-summary/62272</link>
		<comments>http://www.stockbloghub.com/2010/12/14/aapl-company-news-for-december-14-2010-corporate-summary/62272#comments</comments>
		<pubDate>Tue, 14 Dec 2010 20:34:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[BP]]></category>
		<category><![CDATA[BP plc]]></category>
		<category><![CDATA[EMC]]></category>
		<category><![CDATA[EMC Corporation]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[Goodrich Corporation]]></category>
		<category><![CDATA[GR]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JEF]]></category>
		<category><![CDATA[Jefferies Group Inc.]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[SAFM]]></category>
		<category><![CDATA[Sanderson Farms Inc.]]></category>
		<category><![CDATA[TOT]]></category>
		<category><![CDATA[Total SA]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62272</guid>
		<description><![CDATA[• Pfizer (NYSE:PFE) announced a quarterly dividend increase of 11% to $0.20 • Sanderson Farms (NASDAQ:SAFM) reported fiscal fourth quarter earnings of $2.08, beating Zacks Consensus Estimate of $1.69, on revenues of $529.1 million, which was ahead of Zacks Consensus Estimate of $524.0 million • Jefferies (NYSE:JEF) initiated coverage on Total (NYSE:TOT) with a &#8220;buy&#8221; rating and placed British Petroleum (NYSE:BP) at &#8220;hold&#8221; • Goldman Sachs (NYSE:GS) initiated coverage of AmerisourceBergen (NYSE:ABC) and placed the company on its Conviction Buy List • Morgan Stanley (NYSE:MS) removed Apple (NASDAQ:AAPL) from its &#8220;Best Ideas&#8221; List • Janney Montgomery initiated coverage on EMC (NYSE:EMC) with a &#8220;buy&#8221; rating and a target price of $26 • Wells Fargo (NYSE:WFC) upgraded Goodrich (NYSE:GR) to &#8220;outperform&#8221; from &#8220;market perform&#8221; with a target price in the range of $21-$23 • Amgen (NASDAQ:AMGN) announced a study ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/14/aapl-company-news-for-december-14-2010-corporate-summary/62272/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LLY) Eli Lilly&#8217;s Alimta Disappoints for Oncology Pipeline</title>
		<link>http://www.stockbloghub.com/2010/10/17/lly-eli-lillys-alimta-disappoints-for-oncology-pipeline/55125</link>
		<comments>http://www.stockbloghub.com/2010/10/17/lly-eli-lillys-alimta-disappoints-for-oncology-pipeline/55125#comments</comments>
		<pubDate>Sun, 17 Oct 2010 20:11:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55125</guid>
		<description><![CDATA[Eli Lilly’s (LLY) oncology pipeline suffered a setback recently with the company reporting disappointing results on Alimta from a phase III study. Data, presented at the annual meeting of the European Society for Medical Oncology (ESMO), showed that Alimta failed to achieve its primary endpoint in a phase III study that was being conducted in patients suffering from recurrent or metastatic squamous cell cancer of the head and neck (SCCHN). The study was conducted with 795 patients who received treatment with a combination therapy of Alimta and cisplatin. The primary endpoint was overall survival. Although the median overall survival was higher in patients receiving Alimta and cisplatin compared to patients receiving placebo and cisplatin (7.3 months versus 6.3 months), the improvement was not statistically significant. Eli Lilly also said that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/17/lly-eli-lillys-alimta-disappoints-for-oncology-pipeline/55125/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Learns Drug Approval Delayed</title>
		<link>http://www.stockbloghub.com/2010/10/04/teva-teva-pharmaceutical-industries-learns-drug-approval-delayed/53957</link>
		<comments>http://www.stockbloghub.com/2010/10/04/teva-teva-pharmaceutical-industries-learns-drug-approval-delayed/53957#comments</comments>
		<pubDate>Mon, 04 Oct 2010 14:40:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=53957</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd.’s (TEVA) Neutroval failed to receive first-round approval in the US with the Food and Drug Administration (FDA) recently issuing a complete response letter (CRL) for the company’s Biologic License Application (BLA) for the candidate. Teva was looking to get the product approved for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer. Teva’s Biologic License Application for Neutroval was based on results from a clinical program consisting of five studies with more than 680 patients. According to the complete response letter issued by the FDA, Teva needs to provide several items to the agency. However, we are pleased to note that the company will not have to conduct additional studies to gain ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/04/teva-teva-pharmaceutical-industries-learns-drug-approval-delayed/53957/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Drug Priority Review</title>
		<link>http://www.stockbloghub.com/2010/08/01/amgn-amgen-drug-priority-review/43984</link>
		<comments>http://www.stockbloghub.com/2010/08/01/amgn-amgen-drug-priority-review/43984#comments</comments>
		<pubDate>Mon, 02 Aug 2010 00:00:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=43984</guid>
		<description><![CDATA[Amgen (AMGN) recently announced that it has received priority review status from the US Food and Drug Administration (&#8220;FDA&#8221;) for its Biologics License Application (&#8220;BLA&#8221;) for denosumab. Amgen is looking to get denosumab approved for delaying skeletal related events in patients with advanced cancer. The BLA was filed by Amgen in mid-May 2010. Given the priority review status, a final response from the FDA on the candidate’s approvability should be out within 6 months from the filing date (FDA action date: November 18, 2010). The BLA includes data from several studies including three pivotal phase III studies that compared denosumab with Novartis’ (NVS) Zometa. Amgen is seeking approval for this indication in other territories as well including the European Union, Switzerland, Canada, and Australia. Amgen and partner Daiichi-Sankyo are looking ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/01/amgn-amgen-drug-priority-review/43984/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen&#8217;s Pipline Candidate Prolia Earns FDA Approval in U.S.</title>
		<link>http://www.stockbloghub.com/2010/06/03/amgn-amgens-pipline-candidate-prolia-earns-fda-approval-in-u-s/39180</link>
		<comments>http://www.stockbloghub.com/2010/06/03/amgn-amgens-pipline-candidate-prolia-earns-fda-approval-in-u-s/39180#comments</comments>
		<pubDate>Thu, 03 Jun 2010 13:14:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[Putnam Municipal Opportunities Trust]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=39180</guid>
		<description><![CDATA[Amgen Inc. (AMGN) is on a roll with its key pipeline candidate, Prolia, receiving back to back approval in both the EU and the US. While Prolia gained approval in the EU for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures, the US Food and Drug Administration (FDA) approved the product for the treatment of osteoporosis in postmenopausal women at increased risk of fractures or patients who have failed or are intolerant to other osteoporosis treatments. The FDA approval, which came more than a month before the action date of July 25, is a major boost for Amgen. Prolia has been competitively priced at $825 per ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/06/03/amgn-amgens-pipline-candidate-prolia-earns-fda-approval-in-u-s/39180/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Submits to FDA for Denosumab</title>
		<link>http://www.stockbloghub.com/2010/05/21/amgn-amgen-submits-to-fda-for-denosumab/38020</link>
		<comments>http://www.stockbloghub.com/2010/05/21/amgn-amgen-submits-to-fda-for-denosumab/38020#comments</comments>
		<pubDate>Sat, 22 May 2010 05:16:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=38020</guid>
		<description><![CDATA[Amgen Inc. (AMGN) recently submitted a Biologics License Application (BLA) with the US Food and Drug Administration (FDA) for its key pipeline candidate, denosumab. The company is seeking approval for the use of denosumab in delaying skeletal related events in patients with advanced cancer. The BLA includes data from several studies including three pivotal phase III studies that compared denosumab with Novartis’ (NVS) Zometa. Amgen has plans to seek approval for this indication in other territories as well including the European Union, Switzerland, Canada, Australia and Japan. Amgen has a collaboration and licensing agreement with Daiichi-Sankyo for Japan. Denosumab is currently under FDA review for another indication. Amgen is currently seeking approval for the use of denosumab (proposed trade name: Prolia) for the treatment of postmenopausal osteoporosis (PMO). A response ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/21/amgn-amgen-submits-to-fda-for-denosumab/38020/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(UHS) Healthcare Reform &#8211; What Investors Need To Know $$</title>
		<link>http://www.stockbloghub.com/2010/04/30/uhs-healthcare-reform-what-investors-need-to-know/35810</link>
		<comments>http://www.stockbloghub.com/2010/04/30/uhs-healthcare-reform-what-investors-need-to-know/35810#comments</comments>
		<pubDate>Fri, 30 Apr 2010 20:42:34 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospitals]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Community Health Systems]]></category>
		<category><![CDATA[CYH]]></category>
		<category><![CDATA[Health Management Associates Inc]]></category>
		<category><![CDATA[HMA]]></category>
		<category><![CDATA[Tenet Healthcare Corporation]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[THC]]></category>
		<category><![CDATA[UHS]]></category>
		<category><![CDATA[Universal Health Services Inc.]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35810</guid>
		<description><![CDATA[President Obama officially signed Congress’ hotly contested healthcare reform into law on March 23, 2010. When that happened, both sides of the debate filled the newspapers, blogosphere and break rooms with their opinions on the subject… not that they hadn’t been doing just that before as well. But now that the initial furor has died down at least a bit, it seems like a good time to look closely at the facts instead of the hype from either side. In particular, investors should know what the healthcare reform means for the businesses most closely linked to it, such as hospitals and the pharmaceutical industry. What Hospitals Get From Healthcare Reform Let’s start out with the United States hospitals, which include big, publicly traded names such as: Universal Health Services (NYSE: ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/30/uhs-healthcare-reform-what-investors-need-to-know/35810/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma &amp; Biotech Stock Review &#8211; April 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472</link>
		<comments>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:10:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MIL]]></category>
		<category><![CDATA[Millipore Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35472</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARRY) Array BioPharma and Novartis AG Sign Deal for Treating Cancer</title>
		<link>http://www.stockbloghub.com/2010/04/22/arry-array-biopharma-and-novartis-ag-sign-deal-for-treating-cancer/34746</link>
		<comments>http://www.stockbloghub.com/2010/04/22/arry-array-biopharma-and-novartis-ag-sign-deal-for-treating-cancer/34746#comments</comments>
		<pubDate>Thu, 22 Apr 2010 21:27:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Array BioPharma]]></category>
		<category><![CDATA[ARRY]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34746</guid>
		<description><![CDATA[Recently, Array BioPharma Inc. (ARRY) struck a deal with Novartis AG (NVS) to develop its small-molecule methyl ethyl ketone (MEK) inhibitors for treating cancer. The transaction is worth up to $467 million. Array is entitled to receive $45 million in upfront and milestone payments and a further $422 million subject to the achievement of other milestones. The global agreement pertains to the development of ARRY-162, ARRY-300 and other MEK inhibitors. ARRY-162 is currently undergoing early-stage development. The open-label, multiple dose trial is designed to determine the maximum tolerated dose apart from evaluating the safety, pharmacokinetics and pharmacodynamics of the candidate after daily oral administration in advanced cancer patients with solid tumors. The study has established a maximum tolerated dose. Array has started an expansion phase of this trial initially in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/22/arry-array-biopharma-and-novartis-ag-sign-deal-for-treating-cancer/34746/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Beats Expectations &#8211; Guidance Revised to Reflect Health Care Reform Impact</title>
		<link>http://www.stockbloghub.com/2010/04/22/amgn-amgen-beats-expectations-guidance-revised-to-reflect-health-care-reform-impact/34648</link>
		<comments>http://www.stockbloghub.com/2010/04/22/amgn-amgen-beats-expectations-guidance-revised-to-reflect-health-care-reform-impact/34648#comments</comments>
		<pubDate>Thu, 22 Apr 2010 19:49:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34648</guid>
		<description><![CDATA[Amgen (AMGN) reported first quarter earnings per share of $1.28, 5 cents above the Zacks Consensus Estimate of $1.23 and well above the year-ago earnings of $1.07. Total revenues increased 9% to $3,592 million with US and international sales increasing 7% and 16%, respectively. US sales were adversely impacted by $33 million due to the implementation of health care reform provisions. Meanwhile, international sales were boosted by $39 million due to the favorable impact of foreign exchange (Fx) fluctuation. Revenue by Products Revenues of Amgen’s erythropoiesis-stimulating agent (ESA) Aranesp remained unchanged at $627 million (US &#8211; $268 million, down 8%; ex-US &#8211; $359 million, up 7%). US sales were down mainly due to a decline in demand reflecting the negative impact, primarily in the supportive cancer care setting, of additional ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/22/amgn-amgen-beats-expectations-guidance-revised-to-reflect-health-care-reform-impact/34648/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen to Attend American Association for Cancer Research Meeting</title>
		<link>http://www.stockbloghub.com/2010/04/14/amgn-amgen-to-attend-american-association-for-cancer-research-meeting/33717</link>
		<comments>http://www.stockbloghub.com/2010/04/14/amgn-amgen-to-attend-american-association-for-cancer-research-meeting/33717#comments</comments>
		<pubDate>Wed, 14 Apr 2010 21:13:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33717</guid>
		<description><![CDATA[Amgen Inc. (AMGN) should have a strong presence at the upcoming annual meeting of the American Association for Cancer Research (AACR) where the company intends to present preclinical data on its emerging oncology portfolio. Amgen’s oncology portfolio currently consists of 16 molecules which are in varied stages of development. Amgen also has plans to present results from a preclinical study of RANK ligand (RANKL) inhibitor against mammary tumor formation in animal (mouse) models. Besides this, the company will present data from a biomarker analysis of the pivotal phase III study conducted with Vectibix (panitumumab). Vectibix, Amgen’s first fully human monoclonal antibody, is currently approved for the treatment of patients suffering from EGFR expressing metastatic colorectal cancer (mCRC). It is recommended for use in patients whose disease has progressed while on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/14/amgn-amgen-to-attend-american-association-for-cancer-research-meeting/33717/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) GlaxoSmithKline Drug Gets European Commission Approval</title>
		<link>http://www.stockbloghub.com/2010/03/16/gsk-glaxosmithkline-drug-gets-european-commission-approval/30683</link>
		<comments>http://www.stockbloghub.com/2010/03/16/gsk-glaxosmithkline-drug-gets-european-commission-approval/30683#comments</comments>
		<pubDate>Tue, 16 Mar 2010 22:11:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LGND]]></category>
		<category><![CDATA[Ligand Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30683</guid>
		<description><![CDATA[GlaxoSmithKline Plc. (GSK) recently received good news in the form of European approval for its oral thrombopoetin agonist, Revolade (eltrombopag). The European Commission (EC) granted marketing approval to the product for the oral treatment of thrombocytopenia or reduced platelet count in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP). Revolade was granted marketing authorization in the European Union for the treatment of ITP in adult patients who have had their spleen removed, and who do not respond to other treatments, like corticosteroids and immunoglobulins therapies. Revolade also gained approval for use as a second-line treatment option for adult patients who cannot get their spleen removed due to contraindications. Revolade’s approval in the EU does not come as a surprise as the product had already received a positive ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/16/gsk-glaxosmithkline-drug-gets-european-commission-approval/30683/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Awaits US Food and Drug Administration Action on Osteoporosis Drug Candidate</title>
		<link>http://www.stockbloghub.com/2010/02/24/amgn-amgens-awaits-us-food-and-drug-administration-action-on-osteoporosis-drug-candidate/28550</link>
		<comments>http://www.stockbloghub.com/2010/02/24/amgn-amgens-awaits-us-food-and-drug-administration-action-on-osteoporosis-drug-candidate/28550#comments</comments>
		<pubDate>Wed, 24 Feb 2010 18:31:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28550</guid>
		<description><![CDATA[The US Food and Drug Administration (FDA) recently accepted Amgen, Inc.’s (AMGN) complete response submission for Prolia, the company’s lead pipeline candidate, and established an action date of Jul 25, 2010. Amgen is seeking approval for the use of Prolia (denosumab) for the treatment of postmenopausal osteoporosis (PMO). Amgen had initially submitted a Biologic License Application (BLA) for Prolia in Feb 2009. However, Amgen faced a setback in Oct 2009 when the FDA&#8217;s Division of Reproductive and Urologic Products issued a complete response letter asking the company to submit additional information. Amgen submitted its response to the FDA’s complete response letter in late Jan 2010. Among other things, Amgen was asked to submit further information on the design of its previously submitted post-marketing surveillance program. The agency also asked the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/24/amgn-amgens-awaits-us-food-and-drug-administration-action-on-osteoporosis-drug-candidate/28550/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen and Johnson &amp; Johnson See More Safety Check of Anemia Drugs</title>
		<link>http://www.stockbloghub.com/2010/02/17/amgn-amgen-and-johnson-johnson-see-more-safety-check-of-anemia-drugs/28250</link>
		<comments>http://www.stockbloghub.com/2010/02/17/amgn-amgen-and-johnson-johnson-see-more-safety-check-of-anemia-drugs/28250#comments</comments>
		<pubDate>Wed, 17 Feb 2010 23:23:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28250</guid>
		<description><![CDATA[For quite some time, anemia drugs developed by Amgen (AMGN) and Johnson &#38; Johnson (JNJ) have been under the US Food and Drug Administration (FDA) scanner. Recently, the agency announced a new safety plan for both the companies related to the use of these drugs, also known as erythropoiesis–stimulating agents (ESAs), on cancer patients. ESAs are approved for the treatment of anemia that might arise out of kidney failure from certain kinds of chemotherapy. As part of the Risk Evaluation and Mitigation Strategy (REMS), healthcare professionals should provide their patients a Medication Guide explaining the risks related to these drugs. In addition, under the APPRISE (Assisting Providers and Cancer Patients with Risk Information for the Safe Use of ESAs) program, to be launched on March 24, health care professionals  are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/17/amgn-amgen-and-johnson-johnson-see-more-safety-check-of-anemia-drugs/28250/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Earns Positive Results From Phase III Drug Study</title>
		<link>http://www.stockbloghub.com/2010/02/09/amgn-positive-results-on-amgen-drug/27460</link>
		<comments>http://www.stockbloghub.com/2010/02/09/amgn-positive-results-on-amgen-drug/27460#comments</comments>
		<pubDate>Tue, 09 Feb 2010 21:15:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27460</guid>
		<description><![CDATA[Amgen Inc. (AMGN) received a boost recently when the company announced positive results from a pivotal head-to-head phase III study that was conducted with Amgen’s main pipeline candidate, denosumab. The study compared denosumab with Novartis’ (NVS) Zometa in the treatment of bone metastases in 1,901 patients with advanced prostate cancer. Amgen announced that denosumab met the primary and secondary endpoints of the study. Denosumab demonstrated superiority over Zometa in delaying the time to the first on-study skeletal related event (SRE) and reducing the rate of multiple SREs. Both results were statistically significant. Amgen’s shares were up about 2.7% in after-hours trading on the news. Amgen reported that overall rates of adverse events and serious adverse events Incorporatedluding infections, were similar in the two treatment arms. While the rate of incidence ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/09/amgn-positive-results-on-amgen-drug/27460/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen&#8217;s Fourth Quarter Report Misses Expectations but Company Guides Higher</title>
		<link>http://www.stockbloghub.com/2010/01/26/amgn-amgens-fourth-quarter-report-misses-expectations-but-company-guides-higher/26006</link>
		<comments>http://www.stockbloghub.com/2010/01/26/amgn-amgens-fourth-quarter-report-misses-expectations-but-company-guides-higher/26006#comments</comments>
		<pubDate>Tue, 26 Jan 2010 18:13:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26006</guid>
		<description><![CDATA[Amgen (AMGN) reported fourth quarter earnings per share of $1.03, well below the Zacks Consensus Estimate of $1.11 and a cent below the year-ago earnings of $1.04. Full year earnings came in at $4.83, 8 cents below the Zacks Consensus Estimate but 7.8% above the year-ago earnings of $4.48. While fourth quarter total revenues increased 2% to $3,809 million, revenues for the full year declined 2% to $14.6 billion. Total product revenues increased 2% to $3,743 million in the reported quarter. While revenues in the U.S. declined 1% to $2,882 million, international revenues increased 11% to $861 million mainly due to the favorable impact of foreign exchange (Fx) fluctuation, which boosted revenues by approximately $35 million. For the full year, total product revenues declined 2% to $14.4 billion. While U.S. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/26/amgn-amgens-fourth-quarter-report-misses-expectations-but-company-guides-higher/26006/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson and Johnson Tastes Success with Stelara</title>
		<link>http://www.stockbloghub.com/2010/01/20/jnj-johnson-and-johnson-tastes-success-with-stelara/25386</link>
		<comments>http://www.stockbloghub.com/2010/01/20/jnj-johnson-and-johnson-tastes-success-with-stelara/25386#comments</comments>
		<pubDate>Wed, 20 Jan 2010 18:57:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25386</guid>
		<description><![CDATA[Johnson and Johnson (JNJ) has been in news in the last few days, but for the wrong reasons – product recall and allegations of bribery. However, the company received some good news recently on one of its products. Johnson and Johnson announced findings from a phase III clinical study comparing the effectiveness and safety of Stelara (ustekinumab) with Amgen/ Wyeth’s (now a part of Pfizer) (AMGN)/(PFE) Enbrel (etanercept) for the treatment of plaque psoriasis. Earlier in September 2009, Stelara received the US Food and Drug Administration (FDA) approval for the treatment of patients with plaque psoriasis. Johnson and Johnson took a major risk conducting a head-to-head trial with one of the established drugs in this area, Enbrel and it paid off. The drug is one of the most significant drugs ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/20/jnj-johnson-and-johnson-tastes-success-with-stelara/25386/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) GlaxoSmithKline Gains Positive European Medicines Agency Opinion</title>
		<link>http://www.stockbloghub.com/2010/01/06/gsk-glaxosmithkline-gains-positive-european-medicines-agency-opinion/24270</link>
		<comments>http://www.stockbloghub.com/2010/01/06/gsk-glaxosmithkline-gains-positive-european-medicines-agency-opinion/24270#comments</comments>
		<pubDate>Wed, 06 Jan 2010 17:18:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LGND]]></category>
		<category><![CDATA[Ligand Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24270</guid>
		<description><![CDATA[GlaxoSmithKline (GSK) recently received good news with the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issuing a positive opinion for its oral thrombopoetin agonist, Revolade (eltrombopag). Glaxo is seeking approval for the use of Revolade as an oral treatment for thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP). The Committee recommended that Revolade should receive marketing authorization in the European Union for the treatment of ITP in adult patients who have had their spleen removed, and who do not respond to other treatments, like corticosteroids and immunoglobulins therapies. The Committee also recommended the use of Revolade as a second-line treatment option for adult patients who cannot get their spleen removed due to contraindications. Revolade is already approved in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/06/gsk-glaxosmithkline-gains-positive-european-medicines-agency-opinion/24270/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Closer to Prolia Approval</title>
		<link>http://www.stockbloghub.com/2009/12/21/amgn-amgen-closer-to-prolia-approval/23330</link>
		<comments>http://www.stockbloghub.com/2009/12/21/amgn-amgen-closer-to-prolia-approval/23330#comments</comments>
		<pubDate>Tue, 22 Dec 2009 05:38:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23330</guid>
		<description><![CDATA[In a major breakthrough, Amgen (AMGN) received good news with respect to its much awaited drug Prolia (denosumab). Amgen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Prolia, for the treatment of osteoporosis in postmenopausal women and bone loss associated with hormone ablation in men with prostate cancer, both of whom are at increased risk of fractures. The positive opinion is based on data from six phase-III trials. It was observed that Prolia administered as a subcutaneous injection twice yearly (60mg) reduced the incidence of fractures. In addition, we are pleased to see that in all the six studies Prolia&#8217;s was found to increase bone mineral density at all skeletal sites measured. We believe Prolia represents the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/21/amgn-amgen-closer-to-prolia-approval/23330/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(UNH) Healthcare Stock Review &#8211; December 2009 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/12/17/unh-healthcare-stock-review-dec-2009-industry-outlook/23150</link>
		<comments>http://www.stockbloghub.com/2009/12/17/unh-healthcare-stock-review-dec-2009-industry-outlook/23150#comments</comments>
		<pubDate>Fri, 18 Dec 2009 00:58:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Health Care Plans]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BIOS]]></category>
		<category><![CDATA[BioScrip Inc.]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CI]]></category>
		<category><![CDATA[CIGNA Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>
		<category><![CDATA[HUM]]></category>
		<category><![CDATA[Humana Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MOH]]></category>
		<category><![CDATA[Molina Healthcare Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Polypore International Inc]]></category>
		<category><![CDATA[PPO]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23150</guid>
		<description><![CDATA[OVERVIEW The healthcare sector comprises different industries, ranging from managed care organizations, healthcare facilities providers and medical devices manufacturers to biotech and pharmaceutical companies. Consequently, we believe that investors in this sector should be mindful of the different drivers and appropriate metrics associated with the various sub-sectors. In the present scenario, investor sentiment in healthcare continues to be driven by decisions in Congress related to government funding and the state of the broader economy. In view of the ongoing healthcare reform debate in Congress, healthcare policy changes remain an important indicator to investing in the sector. Even though legislation &#8212; which aims to cover nearly all Americans by providing government subsidies to help pay premiums irrespective of health or income &#8212; was passed in the House of Representatives, it is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/17/unh-healthcare-stock-review-dec-2009-industry-outlook/23150/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Drug Meets Study Goal</title>
		<link>http://www.stockbloghub.com/2009/12/16/celg-celgene-drug-meets-study-goal/23009</link>
		<comments>http://www.stockbloghub.com/2009/12/16/celg-celgene-drug-meets-study-goal/23009#comments</comments>
		<pubDate>Wed, 16 Dec 2009 22:50:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23009</guid>
		<description><![CDATA[Celgene Corp. (CELG) recently disclosed that its drug candidate, apremilast, for treating patients with moderate-to-severe plaque-type psoriasis, met key goals in a mid-stage study (n=352). The multi-center study, in which apremilast reduced the severity of moderate-to-severe psoriasis, saw patients receiving 10 mg, 20mg or 30mg of apremilast twice daily, or placebo. The data revealed that 41 % patients treated with 30 milligrams of apremilast, twice daily, underwent a 75 % reduction in symptoms. The symptoms were measured by a score known as the Psoriasis Area and Severity Index (PASI-75) after 16 weeks. However, only 6 % of patients who received a placebo reached that score. Furthermore, 29% of patients in the 20mg arm of apremilast and 11% of patients in the 10mg arm achieved a PASI-75 respectively. Celgene intends to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/16/celg-celgene-drug-meets-study-goal/23009/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen&#8217;s Rheumatoid Arthritis Candidate Effective</title>
		<link>http://www.stockbloghub.com/2009/12/14/biib-biogens-rheumatoid-arthritis-candidate-effective/22761</link>
		<comments>http://www.stockbloghub.com/2009/12/14/biib-biogens-rheumatoid-arthritis-candidate-effective/22761#comments</comments>
		<pubDate>Tue, 15 Dec 2009 01:28:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[Minerals Technologies Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MTX]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22761</guid>
		<description><![CDATA[Biogen Idec (BIIB) and Genentech Inc., a wholly owned member of the Roche Group (RHHBY), recently reported positive phase III results on their rheumatoid arthritis (RA) candidate, ocrelizumab. Results from the study (STAGE) showed that the humanized anti-CD20 monoclonal antibody, when given in combination with methotrexate (MTX), met its primary endpoint of improving signs and symptoms in RA patients who were not getting an adequate response to MTX at either 24 or 48 weeks. While these results were encouraging, there could be some concern regarding the safety profile of the candidate as the companies reported a higher percentage of serious infections in the pooled ocrelizumab groups when compared to the placebo group. Safety analyses from the study are ongoing and will be presented at an upcoming medical meeting. The international, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/14/biib-biogens-rheumatoid-arthritis-candidate-effective/22761/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Teva Pharmaceutical Industries Seeks FDA Approval for XM02</title>
		<link>http://www.stockbloghub.com/2009/12/09/amgn-teva-pharmaceutical-industries-seeks-fda-approval-for-xm02/22384</link>
		<comments>http://www.stockbloghub.com/2009/12/09/amgn-teva-pharmaceutical-industries-seeks-fda-approval-for-xm02/22384#comments</comments>
		<pubDate>Wed, 09 Dec 2009 23:50:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22384</guid>
		<description><![CDATA[Amgen, Inc.’s (AMGN) Neupogen could face competition in the near future from generic player, Teva Pharmaceutical Industries Ltd. (TEVA). Teva recently submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for XM02, a granulocyte colony-stimulating factor (G-CSF). Potential approval in 2010 could lead to the product launch in late 2010/early 2011. Teva is looking to get the product approved for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer. XM02 is similar to Amgen’s Neupogen and will compete directly with Neupogen once launched. XM02 is already approved in the European Union where a biosimilars pathway exists. It is available in several markets in the EU under the name TevaGrastim – additional ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/09/amgn-teva-pharmaceutical-industries-seeks-fda-approval-for-xm02/22384/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Beats &#8211; Raises Guidance</title>
		<link>http://www.stockbloghub.com/2009/10/22/amgn-amgen-beats-raises-guidance/18516</link>
		<comments>http://www.stockbloghub.com/2009/10/22/amgn-amgen-beats-raises-guidance/18516#comments</comments>
		<pubDate>Thu, 22 Oct 2009 22:50:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18516</guid>
		<description><![CDATA[Amgen (AMGN) reported third quarter earnings per share of $1.47, well above the Zacks Consensus Estimate of $1.26 and 21% above the year-ago earnings of $1.21. Cost cuts and a lower tax rate helped boost the top-line despite a 2% decline in total revenues, which came in at $3,812 million. Total product sales decreased 1% to $3,736 million. While sales in the U.S. were relatively unchanged at $2,918 million, international sales declined 4% to $818 million mainly due to the unfavorable impact of foreign exchange (Fx) fluctuation, which affected sales by approximately $76 million. Aranesp sales declined 19% to $685 million (U.S. &#8211; $333 million, down 27%; ex-U.S. &#8211; $352 million, down 9%), mainly due to a decline in demand reflecting the negative impact, primarily in the supportive cancer care ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/22/amgn-amgen-beats-raises-guidance/18516/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) ($AMGN) Amgen Drug Approval Delayed</title>
		<link>http://www.stockbloghub.com/2009/10/21/amgn-amgn-amgen-drug-approval-delayed/18403</link>
		<comments>http://www.stockbloghub.com/2009/10/21/amgn-amgn-amgen-drug-approval-delayed/18403#comments</comments>
		<pubDate>Wed, 21 Oct 2009 22:13:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18403</guid>
		<description><![CDATA[Yesterday, Amgen Inc (AMGN) announced that the US Food and Drug Administration (FDA) delayed the approval of its osteoporosis drug denosumab, with a proposed trade name of Prolia. In response to the Biologic License Applications (BLA) filed by Amgen in Feb 2009 for Prolia, the Complete Response Letter [CRL] issued by the FDA requested several items Incorporatedluding further information on the design of Amgen&#8217;s previously submitted post-marketing surveillance program. The FDA has asked the company to develop a strategy to evaluate the risks of Prolia. However, the agency did not ask for further clinical trials, which would have resulted in a longer delay. Management believes that it can satisfy the queries of the FDA. The company intends to market Prolia for the treatment and prevention of postmenopausal osteoporosis [PMO] and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/21/amgn-amgn-amgen-drug-approval-delayed/18403/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Laboratories Outperforms &amp; Raises</title>
		<link>http://www.stockbloghub.com/2009/10/16/abt-abbott-laboratories-outperforms-raises/17688</link>
		<comments>http://www.stockbloghub.com/2009/10/16/abt-abbott-laboratories-outperforms-raises/17688#comments</comments>
		<pubDate>Fri, 16 Oct 2009 22:56:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17688</guid>
		<description><![CDATA[Abbott Laboratories (ABT) reported third quarter earnings of 92 cents per share, 2 cents above the Zacks Consensus Estimate of 90 cents. Results were above the company’s guidance of 88 – 90 cents. Earnings increased 16.5% from the year-ago period. Total revenues grew 3.5% to $7,761 million. Revenues were negatively impacted by 4.9% due to foreign exchange (Fx) headwinds. Sales in the Pharmaceutical division totaled $4,055 million, down 1.6% and negatively impacted by about 5.5% due to Fx. Strong Humira and lipid franchise sales were offset by weak performance of Depakote, which is facing intense generic competition. The lipid franchise posted sales of $545 million. The recent launch of TriLipix, which will be co-promoted with AstraZeneca (AZN), should help drive lipid franchise sales. Meanwhile, we were pleased to see that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/abt-abbott-laboratories-outperforms-raises/17688/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Two Pharmas Are Better Than One &#8211; Here Are the Ones to Buy in This Merger-Mad Industry</title>
		<link>http://www.stockbloghub.com/2009/10/16/abt-two-pharmas-are-better-than-one-here-are-the-ones-to-buy-in-this-merger-mad-industry/17681</link>
		<comments>http://www.stockbloghub.com/2009/10/16/abt-two-pharmas-are-better-than-one-here-are-the-ones-to-buy-in-this-merger-mad-industry/17681#comments</comments>
		<pubDate>Fri, 16 Oct 2009 20:27:30 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Crucell N.v.]]></category>
		<category><![CDATA[CRXL]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17681</guid>
		<description><![CDATA[Tony Daltorio, Investment U Research Pharmaceutical companies have launched themselves into the fall season with a vengeance, gobbling up acquisitions like dots on a Pac-Man board. The most notable recent buyout was a deal that sees Abbott Laboratories (NYSE: ABT) expand both its product range and its presence in notable emerging nations with its purchase of Belgian-based Solvay Group’s pharmaceutical arm for a $6.5 billion fee. That price tag is just one indication of the money washing around this industry these days, which makes the current consolidation trend chock full of profitable opportunities. As Investment U’s own “takeover tracker” Louis Basenese does all the time, he positions investors for some pretty lucrative short-term profits by buying takeover targets, then riding those deals all the way into long-term profits by purchasing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/abt-two-pharmas-are-better-than-one-here-are-the-ones-to-buy-in-this-merger-mad-industry/17681/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

